<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TAN</journal-id>
<journal-id journal-id-type="hwp">sptan</journal-id>
<journal-title>Therapeutic Advances in Neurological Disorders</journal-title>
<issn pub-type="ppub">1756-2856</issn>
<issn pub-type="epub">1756-2864</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1756285612454323</article-id>
<article-id pub-id-type="publisher-id">10.1177_1756285612454323</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>White matter dementia</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Filley</surname><given-names>Christopher M.</given-names></name>
</contrib>
<aff id="aff1-1756285612454323">Behavioral Neurology Section, 12631 East 17<sup>th</sup> Avenue, Aurora, Colorado, USA</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-1756285612454323"><email>christopher.filley@ucdenver.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>9</month>
<year>2012</year>
</pub-date>
<volume>5</volume>
<issue>5</issue>
<fpage>267</fpage>
<lpage>277</lpage>
<permissions>
<copyright-statement>© The Author(s), 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>White matter dementia (WMD) is a syndrome introduced in 1988 to highlight the potential of cerebral white matter disorders to produce cognitive loss of sufficient severity to qualify as dementia. Neurologists have long understood that such a syndrome can occur, but the dominance of gray matter as the locus of higher function has strongly directed neurobehavioral inquiry to the cerebral cortex while white matter has received less attention. Contemporary neuroimaging has been crucial in enabling the recognition of white matter abnormalities in a host of disorders, and the correlation of these changes with cognitive performance. Comprising about half the brain, white matter is prominently or exclusively involved in well over 100 disorders, in each of which white matter dysfunction can potentially cause or contribute to dementia. Neuropsychological findings from ten categories of white matter disorder lead to a convergence of findings that document remarkable neurobehavioral commonality among the dementias produced. More recently, the syndrome of mild cognitive dysfunction (MCD) has been introduced to expand the concept of WMD by proposing a precursor syndrome related to early white matter neuropathology. WMD and MCD inform the understanding of how white matter contributes to normal and abnormal cognition, and the specific neuroanatomic focus of these syndromes may enhance the diagnosis and treatment of many disabling disorders that do not primarily implicate the cerebral cortex. Forming essential connections within widely distributed neural networks, white matter is critical for rapid and efficient information transfer that complements the information processing of gray matter. As neuroimaging continues to advance, further information on white matter structure can be expected, and behavioral neurology will play a central role in elucidating the functional significance of these emerging data. By emphasizing the contribution of myelinated systems to higher function, the study of white matter and cognition represents investigation of the basic neuroscience of human behavior.</p>
</abstract>
<kwd-group>
<kwd>White matter</kwd>
<kwd>dementia</kwd>
<kwd>toluene leukoencephalopathy</kwd>
<kwd>multiple sclerosis</kwd>
<kwd>myelin</kwd>
<kwd>magnetic resonance spectroscopy</kwd>
<kwd>diffusion tensor imaging</kwd>
<kwd>disconnection</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1756285612454323" sec-type="intro">
<title>Introduction</title>
<p>Behavioral neurology is commonly described as the study of higher cortical function, an association held so firmly by many neuroscientists that a “corticocentric” view of behavior is often adopted without question (<xref ref-type="bibr" rid="bibr51-1756285612454323">Parvizi, 2009</xref>). However, a wealth of evidence supports the notion that brain-behavior relationships extend far beyond the syndromes resulting from damage to the cerebral cortex (<xref ref-type="bibr" rid="bibr30-1756285612454323">Geschwind, 1965</xref>; <xref ref-type="bibr" rid="bibr59-1756285612454323">Schmahmann et al., 2008</xref>; <xref ref-type="bibr" rid="bibr15-1756285612454323">Filley, 2010</xref>; <xref ref-type="bibr" rid="bibr16-1756285612454323">Filley, 2011a</xref>). Whereas the importance of the cortical mantle in elaborating human behavior is firmly established, the contributions of non-cortical regions – the subcortical gray matter and the white matter – cannot be neglected. Experienced neurologists recognize the potential for damage to these regions to produce significant neurobehavioral dysfunction, but the traditional dominance of the cortical gray matter in the neuroscience of behavior has to some extent hampered investigation of the full range of brain-behavior relationships. This limitation is nowhere more evident than in the study of dementia.</p>
<p>The growing problem of Alzheimer’s disease (AD) overshadows the entire field of dementia, and its well-known neuropathology naturally directs attention to the cerebral cortex in the investigation of etiopathogenesis, clinical phenomenology, and treatment (<xref ref-type="bibr" rid="bibr54-1756285612454323">Querfurth and LaFerla, 2010</xref>). But many other dementias result from neuropathology subjacent to the cortex. The subcortical dementias, the most prominent being Huntington’s disease (HD) and Parkinson’s disease (PD), are associated with neuropathology in the basal ganglia and other deep gray matter structures, and despite some criticism, the concept of subcortical dementia has persisted as a useful contrasting clinical syndrome to the cortical dementia of AD. White matter disorders are often included in the subcortical dementias, alternatively known as frontal-subcortical dementias (<xref ref-type="bibr" rid="bibr10-1756285612454323">Bonelli and Cummings, 2008</xref>), but uncertainty lingers about the importance of white matter damage in producing neurobehavioral effects, and demented patients with white matter lesions are frequently assumed to have coexistent cortical neuropathology to explain their cognitive loss.</p>
<p>White matter, however, merits systematic consideration as a brain component critical to behavioral neurology (<xref ref-type="bibr" rid="bibr19-1756285612454323">Filley et al., 1988</xref>; <xref ref-type="bibr" rid="bibr59-1756285612454323">Schmahmann et al., 2008</xref>; <xref ref-type="bibr" rid="bibr15-1756285612454323">Filley, 2010</xref>; <xref ref-type="bibr" rid="bibr16-1756285612454323">Filley, 2011a</xref>; <xref ref-type="bibr" rid="bibr18-1756285612454323">Filley, 2012</xref>). Comprising about half the human brain, white matter provides the essential connectivity of distributed neural networks coursing within and between the hemispheres to subserve a host of neurobehavioral functions. White matter expands the operational capacity of neurons by enabling the rapid and efficient transfer of information that complements the information processing of gray matter.</p>
<p>The increasing interest in white matter in behavioral neurology has been stimulated by impressive advances of neuroimaging, beginning with the introduction of magnetic resonance imaging (MRI) in the early 1980s. For the first time, white matter could be visualized and correlated with clinical phenomena without the need for autopsy. This advantage allowed application of the lesion method, a time-honored approach at the core of behavioral neurology, to lesions of white matter in the same manner as has been the case for gray matter. An impressive data base has since been generated to support the role of white matter in cognition and emotion. In addition to the well-recognized sensorimotor deficits that can accompany white matter involvement – such as visual loss, paresis, spasticity, ataxia, gait disorder, and incontinence – a wide variety of neurobehavioral dysfunction can occur, including focal disconnection syndromes, neuropsychiatric disorders including depression, and cognitive impairment often sufficiently severe to merit the term dementia (<xref ref-type="bibr" rid="bibr18-1756285612454323">Filley, 2012</xref>).</p>
<p>White matter has a legitimate position in the study of dementia. The neuropathology of white matter disorders is typically diffuse or widespread, thus disrupting many networks simultaneously and producing a multi-domain syndrome that merits the term dementia. Beyond the well-recognized focal neurobehavioral syndromes of white matter (<xref ref-type="bibr" rid="bibr30-1756285612454323">Geschwind, 1965</xref>), dementia resulting from white matter lesions is fact far more common (<xref ref-type="bibr" rid="bibr16-1756285612454323">Filley, 2011a</xref>). This article will review and update the syndrome of white matter dementia (WMD), a term introduced more than two decades ago (<xref ref-type="bibr" rid="bibr19-1756285612454323">Filley et al., 1988</xref>) to call attention to the cognitive sequelae of brain white matter disorders.</p>
</sec>
<sec id="section2-1756285612454323">
<title>A brief neuropathologic overview of dementia</title>
<p>The acquired loss of cognitive competence meant by the term dementia implies that brain function is compromised to the extent that multiple cognitive domains are affected and neither normal cognition nor customary social and occupational function can be maintained (<xref ref-type="bibr" rid="bibr47-1756285612454323">McKhann et al., 1984</xref>; <xref ref-type="bibr" rid="bibr6-1756285612454323">American Psychiatric Association, 1994</xref>). One approach to the understanding of dementia can begin with focusing on the brain regions in which dysfunction is thought to occur (<xref ref-type="bibr" rid="bibr17-1756285612454323">Filley, 2011b</xref>). A classification based on neuropathology not only informs diagnostic evaluation but highlights the diversity of systems that each contribute to the phenomenology of cognitive function. To begin, the cerebral cortex, including the hippocampus and entorhinal region, is regarded as the primary site of neuropathology in AD, the classic cortical dementia, and neuritic plaques and neurofibrillary tangles remain the targets of most investigation directed at this increasingly threatening medical and societal challenge. The subcortical dementias, meanwhile, including but not limited to HD and PD, are associated with major neuropathology in deep gray matter nuclei such as the caudate and substantia nigra (<xref ref-type="bibr" rid="bibr10-1756285612454323">Bonelli and Cummings, 2008</xref>). A third category can also be invoked, that of mixed dementia, in which neuropathology affects both cortical and deep cerebral structures; examples include multi-infarct dementia and Creutzfeldt-Jakob Disease. A fourth and least familiar category is one characterized by significant neuropathology in white matter. Dementia in this context results from diffuse or widespread involvement of association and commissural tracts that provide critical intra- and interhemispheric connectivity enabling the structure and function of distributed neural networks mediating cognition (<xref ref-type="bibr" rid="bibr59-1756285612454323">Schmahmann et al., 2008</xref>; <xref ref-type="bibr" rid="bibr18-1756285612454323">Filley, 2012</xref>). Variable degrees of overlap undoubtedly exist between these four categories, to some extent blurring neuropathologic distinctions. White matter has been found abnormal in AD, for example, and conversely, cortical involvement can be detected in multiple sclerosis (MS). However, AD is characterized by massive cortical neuronal loss, with secondary white matter changes from Wallerian degeneration, whereas in MS, primary white matter damage occurs as a consequence of inflammatory demyelination. These neuropathologic differences imply that each dementia category features a unique profile of cognitive impairment, and substantial evidence exists for these distinctions (<xref ref-type="bibr" rid="bibr17-1756285612454323">Filley, 2011b</xref>; <xref ref-type="bibr" rid="bibr18-1756285612454323">Filley, 2012</xref>). Taken as a whole, therefore, this structurally-based classification assists in the understanding the diagnosis, etiopathogenesis, and treatment of dementia in all its forms (<xref ref-type="bibr" rid="bibr17-1756285612454323">Filley, 2011b</xref>; <xref ref-type="bibr" rid="bibr18-1756285612454323">Filley 2012</xref>).</p>
</sec>
<sec id="section3-1756285612454323">
<title>The syndrome of white matter dementia</title>
<p>Neurologists since at least the time of Jean-Martin Charcot in the 19<sup>th</sup> century have appreciated that cerebral white matter disease may produce important neurobehavioral sequelae, including dementia. In 1988, based largely on experience with toluene leukoencephalopathy (<xref ref-type="bibr" rid="bibr20-1756285612454323">Filley et al., 1990</xref>) and MS (<xref ref-type="bibr" rid="bibr29-1756285612454323">Franklin et al., 1989</xref>), the syndrome of WMD was proposed to describe the dementia.that can accompany cerebral white matter involvement. Implicit in the idea was that white matter disorders typically involve widespread areas of the brain, and the disruption of myelinated tracts affects cognition regardless of the specific neuropathology present. WMD is thus defined as a dementia syndrome resulting from diffuse or multifocal cerebral white matter damage (<xref ref-type="bibr" rid="bibr19-1756285612454323">Filley et al., 1988</xref>; <xref ref-type="bibr" rid="bibr22-1756285612454323">Filley, 1998</xref>; <xref ref-type="bibr" rid="bibr59-1756285612454323">Schmahmann et al., 2008</xref>).</p>
<p>WMD can be caused by disorders within ten categories, constituting a wide array of neuropathologic states with the notable exception of neurodegenerative disease (<xref ref-type="table" rid="table1-1756285612454323">Table 1</xref>). Well over 100 disorders can lead to WMD, a list that is constantly expanding as MRI discloses new entities and older ones are better understood (<xref ref-type="bibr" rid="bibr18-1756285612454323">Filley, 2012</xref>). These diseases, injuries, and intoxications may occur at any age and in a wide variety of medical settings, highlighting the broad relevance of the WMD concept. Discussion of all these entities, beyond the scope of this review, can be found elsewhere (<xref ref-type="bibr" rid="bibr18-1756285612454323">Filley, 2012</xref>). Perusal of current neurologic literature, however, quickly discloses the breadth and depth of the investigations now being conducted. A particularly vigorous research area is cerebrovascular disease, and the phenomenon of leukoaraiosis has stimulated much study as a cause of cognitive dysfunction (<xref ref-type="bibr" rid="bibr37-1756285612454323">Inzitari et al., 2009</xref>; <xref ref-type="bibr" rid="bibr12-1756285612454323">Debette and Markus, 2010</xref>).</p>
<table-wrap id="table1-1756285612454323" position="float">
<label>Table 1.</label>
<caption><p>Neuropathological categories of white matter disorder, with selected examples.</p></caption>
<graphic alternate-form-of="table1-1756285612454323" xlink:href="10.1177_1756285612454323-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
</colgroup>
<tbody>
<tr>
<td>Genetic</td>
<td>Metabolic</td>
</tr>
<tr>
<td> Metachromatic leukodystrophy</td>
<td> Cobalamin (vitamin B<sub>12</sub>) deficiency</td>
</tr>
<tr>
<td>Demyelinative</td>
<td>Vascular</td>
</tr>
<tr>
<td> Multiple sclerosis</td>
<td> Binswanger’s disease</td>
</tr>
<tr>
<td>Infectious</td>
<td>Traumatic</td>
</tr>
<tr>
<td> HIV-associated dementia</td>
<td> Traumatic brain injury</td>
</tr>
<tr>
<td>Inflammatory</td>
<td>Neoplastic</td>
</tr>
<tr>
<td> Systemic lupus erythematosus</td>
<td> Gliomatosis cerebri</td>
</tr>
<tr>
<td>Toxic</td>
<td>Hydrocephalic</td>
</tr>
<tr>
<td> Toluene leukoencephalopathy</td>
<td> Normal pressure hydrocephalus</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>The clinical profile of WMD has been investigated by considering a variety of white matter disorders in parallel. Initial efforts were directed at distinguishing WMD from both cortical and subcortical dementia, and studies comparing MS with AD (<xref ref-type="bibr" rid="bibr21-1756285612454323">Filley et al., 1989</xref>) and MS with HD (<xref ref-type="bibr" rid="bibr42-1756285612454323">Lafosse et al., 2007</xref>) were instructive. These and other reports helped establish that WMD differs from both cortical and subcortical dementia, particularly in early stages of the disorder before severe dementia has developed. WMD is distinguished from cortical dementia by relative normalcy of language and declarative memory encoding while cognitive speed, executive function, and sustained attention are impaired, and from subcortical dementia by sparing of procedural memory and extrapyramidal function (<xref ref-type="bibr" rid="bibr19-1756285612454323">Filley, 1988</xref>; <xref ref-type="bibr" rid="bibr22-1756285612454323">Filley, 1998</xref>; <xref ref-type="bibr" rid="bibr18-1756285612454323">Filley, 2012</xref>). Core distinctions between the three syndromes, shown in <xref ref-type="table" rid="table2-1756285612454323">Table 2</xref>, are most apparent in specific aspects of memory and language.</p>
<table-wrap id="table2-1756285612454323" position="float">
<label>Table 2.</label>
<caption><p>Core distinctions between cortical, white matter, and subcortical dementia.</p></caption>
<graphic alternate-form-of="table2-1756285612454323" xlink:href="10.1177_1756285612454323-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Domain</th>
<th align="center">Cortical</th>
<th align="center">White Matter</th>
<th align="center">Subcortical</th>
</tr>
</thead>
<tbody>
<tr>
<td>Declarative Memory</td>
<td>Encoding deficit</td>
<td>Retrieval deficit</td>
<td>Retrieval deficit</td>
</tr>
<tr>
<td>Procedural Memory</td>
<td>Normal</td>
<td>Normal</td>
<td>Impaired</td>
</tr>
<tr>
<td>Language</td>
<td>Impaired</td>
<td>Normal</td>
<td>Normal</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>As time progressed and new data emerged, the importance of cognitive slowing became apparent. Whereas slowed cognition was long associated with the subcortical dementias (<xref ref-type="bibr" rid="bibr2-1756285612454323">Albert et al. 1974</xref>; <xref ref-type="bibr" rid="bibr46-1756285612454323">McHugh and Folstein, 1975</xref>), and indeed all dementia patients may struggle with slowed processing speed, the advent of advanced neuroimaging allowed detailed study of white matter tracts <italic>in vivo</italic>, and cognitive processing speed has been tightly linked with the integrity of myelinated systems (<xref ref-type="bibr" rid="bibr65-1756285612454323">Turken et al., 2008</xref>; <xref ref-type="bibr" rid="bibr52-1756285612454323">Penke et al., 2010</xref>). Disorders that impair central impulse conduction thus produce slowed cognition – a reasonable assumption now increasingly supported by neuroimaging evidence – and cognitive slowing has become a distinctive feature of WMD (<xref ref-type="bibr" rid="bibr18-1756285612454323">Filley, 2012</xref>). With this addition to the list of cognitive deficits and areas of relative strength, the current formulation of the clinical profile of WMD is shown in <xref ref-type="table" rid="table3-1756285612454323">Table 3</xref>.</p>
<table-wrap id="table3-1756285612454323" position="float">
<label>Table 3.</label>
<caption><p>The profile of white matter dementia.</p></caption>
<graphic alternate-form-of="table3-1756285612454323" xlink:href="10.1177_1756285612454323-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
</colgroup>
<tbody>
<tr>
<td>Cognitive slowing</td>
</tr>
<tr>
<td>Executive dysfunction</td>
</tr>
<tr>
<td>Sustained attention deficit</td>
</tr>
<tr>
<td>Memory retrieval deficit</td>
</tr>
<tr>
<td>Visuospatial impairment</td>
</tr>
<tr>
<td>Psychiatric disorder</td>
</tr>
<tr>
<td>Relatively preserved language</td>
</tr>
<tr>
<td>Normal extrapyramidal function</td>
</tr>
<tr>
<td>Normal procedural memory</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>One of the recurring questions about the WMD concept is the degree to which co-existent gray matter neuropathology may explain the cognitive deficits. Relatively few cognitive disorders affect white matter exclusively, and as discussed elsewhere (<xref ref-type="bibr" rid="bibr18-1756285612454323">Filley, 2012</xref>), the relative contributions of white and gray matter changes may both be relevant. However, the accumulated weight of correlational evidence justifies the existence of WMD in many patients with many disorders (<xref ref-type="bibr" rid="bibr18-1756285612454323">Filley, 2012</xref>). Toluene leukoencephalopathy, for example, is a convincing cause of WMD, with confirmatory neuroimaging, neuropsychological (<xref ref-type="bibr" rid="bibr67-1756285612454323">Yücel et al., 2008</xref>) and neuropathologic (<xref ref-type="bibr" rid="bibr3-1756285612454323">Al-Hajri and Del Bigio, 2010</xref>) evidence continuing to support the earlier reports making this claim (<xref ref-type="bibr" rid="bibr36-1756285612454323">Hormes et al. 1986</xref>; <xref ref-type="bibr" rid="bibr55-1756285612454323">Rosenberg et al., 1988</xref>; <xref ref-type="bibr" rid="bibr20-1756285612454323">Filley et al., 1990</xref>; <xref ref-type="bibr" rid="bibr24-1756285612454323">Filley et al., 2004</xref>). Even in MS, in which gray matter neuropathology has long been recognized, the WMD model appears justified, at least in the initial stages of the disease. Cognitive decline begins early in MS (<xref ref-type="bibr" rid="bibr5-1756285612454323">Amato et al., 2010</xref>), and while all patients have white matter lesions, cortical lesions are found in only 8% of children (<xref ref-type="bibr" rid="bibr1-1756285612454323">Absinta et al., 2011</xref>) and 38% of adults with newly apparent disease (<xref ref-type="bibr" rid="bibr44-1756285612454323">Lucchinetti et al., 2011</xref>). Moreover, the cognitive profile of MS resembles other that of white matter disorders more than AD (<xref ref-type="bibr" rid="bibr21-1756285612454323">Filley et al., 1989</xref>), suggesting that tract demyelination is the major determinant of cognitive decline, at least until later in the course.</p>
</sec>
<sec id="section4-1756285612454323">
<title>Mild cognitive dysfunction</title>
<p>WMD is a syndrome based on the correlation of white matter lesions visible on conventional MRI with a specific profile of cognitive deficits. The early years of the MRI era made possible this research, but recent advances in neuroimaging have revealed an intriguing new finding: the normal-appearing white matter (NAWM) on conventional MRI may not be normal when examined with more sensitive techniques. These newer techniques, among them magnetic resonance spectroscopy (MRS), magnetization transfer imaging (MTI), and diffusion tensor imaging (DTI), permit the investigation of NAWM and regularly uncover microstructural abnormalities. A rapidly expanding list of conditions can now be assembled in which the NAWM is not normal when queried by one or more of these methods (<xref ref-type="table" rid="table4-1756285612454323">Table 4</xref>). Given the neurobehavioral importance of macrostructural white matter lesions, an appropriate next question concerns the potential effects of more subtle abnormalities in NAWM.</p>
<table-wrap id="table4-1756285612454323" position="float">
<label>Table 4.</label>
<caption><p>Some conditions in which the normal-appearing white matter may be abnormal.</p></caption>
<graphic alternate-form-of="table4-1756285612454323" xlink:href="10.1177_1756285612454323-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<tbody>
<tr>
<td>Metachromatic leukodystrophy</td>
<td>Leukoariaiosis</td>
</tr>
<tr>
<td>Phenylketonuria</td>
<td>Traumatic brain injury</td>
</tr>
<tr>
<td>Neurofibromatosis</td>
<td>Glioma</td>
</tr>
<tr>
<td>Tuberous sclerosis</td>
<td>Normal pressure hydrocephalus</td>
</tr>
<tr>
<td>Myotonic dystrophy</td>
<td>Aging</td>
</tr>
<tr>
<td>Fragile X tremor-ataxia syndrome</td>
<td>Autism</td>
</tr>
<tr>
<td>Multiple sclerosis</td>
<td>Attention deficits hyperactivity disorder</td>
</tr>
<tr>
<td>HIV infection</td>
<td>Aggression</td>
</tr>
<tr>
<td>Systemic lupus erythematosus</td>
<td>Bipolar disorder</td>
</tr>
<tr>
<td>Alcoholism</td>
<td>Schizophrenia</td>
</tr>
<tr>
<td>Hypoxia</td>
<td>Alzheimer’s disease</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Studies of WMD as well as clinical experience suggest the existence of a less severe cognitive syndrome associated with less obvious white matter neuropathology. A good example of the potentially wide range of white matter involvement can be seen in toxic leukoencephalopathy, in which a spectrum of MRI and neuropathological changes occurs, with the resultant neurobehavioral dysfunction being concomitantly mild, moderate, or severe (<xref ref-type="bibr" rid="bibr23-1756285612454323">Filley and Kleinschmidt-DeMasters, 2001</xref>; <xref ref-type="bibr" rid="bibr24-1756285612454323">Filley et al., 2004</xref>). The concept of a spectrum of white matter alterations can be extended to suggest that NAWM abnormalities may be associated with subtle cognitive loss even before macrostructural lesions appear on conventional MRI.</p>
<p>In this context, the category of inflammatory white matter disease became relevant as a clinical model for studying the effects of NAWM changes on cognition. Systemic lupus erythematosus (SLE) presented itself an ideal disease for this purpose as an illness that typically affects young adults with little or no other neuropathology, features white matter hyperintensities as its most common conventional MRI finding, and frequently affects cognition at an early stage (<xref ref-type="bibr" rid="bibr40-1756285612454323">Kozora and Filley, 2011</xref>). MRS studies of frontal NAWM in fact disclosed that increased choline (Ch), a marker of inflammation and demyelination, correlated with impaired processing speed, attention, and executive dysfunction in SLE patients whose gray and white matter volumes did not differ from controls (<xref ref-type="bibr" rid="bibr25-1756285612454323">Filley et al., 2009</xref>). The elevation of Ch suggested myelinopathy, presumably immune-mediated, since the axonal marker N-acetyl aspartate was found to be normal (<xref ref-type="bibr" rid="bibr25-1756285612454323">Filley et al., 2009</xref>).</p>
<p>From these and other findings, the term mild cognitive dysfunction (MCD) was introduced (<xref ref-type="bibr" rid="bibr40-1756285612454323">Kozora and Filley, 2011</xref>). MCD is an early cognitive syndrome in SLE patients, and the correlation of cognitive slowing, executive dysfunction, and inattention with increased Ch suggests that in some patients MCD results from insidious white matter neuropathology. More study is needed to confirm the relationship of microstructural white matter abnormalities and cognition, but this model may inform the understanding of how subtle white matter changes disrupt cognition, Described specifically in SLE, MCD may also apply to other disorders in which white matter is involved, and many possibilities in improving early diagnosis and treatment are apparent. From a cognitive perspective, the deficits of MCD are remarkably similar to, but less severe than, those of WMD, again supporting the legitimacy of WMD as a dementia syndrome.</p>
<p>The relationship of MCD to WMD can be seen as based in white matter dysfunction that includes both macrostructural and microstructural involvement. <xref ref-type="fig" rid="fig1-1756285612454323">Figure 1</xref> depicts in schematic form the proposed general relationship between cognitive decline and white matter involvement of varying severity. The categories of MCD and WMD require further study using a range of disease models, as distinctions between these syndromes need clarification and correlation with neuropathological changes, but the notion of increasing white matter change producing advancing degrees of cognitive loss serves as a paradigm for exploring the entire range of white matter involvement.</p>
<fig id="fig1-1756285612454323" position="float">
<label>Figure 1.</label>
<caption><p>Proposed schematic relationship between white matter and cognition (WM – white matter, NAWM – normal-appearing white matter; MRI – magnetic resonance imaging).</p></caption>
<graphic xlink:href="10.1177_1756285612454323-fig1.tif"/></fig>
<p>An obvious parallel to MCD in behavioral neurology is mild cognitive impairment (MCI; <xref ref-type="bibr" rid="bibr53-1756285612454323">Petersen, 2011</xref>), a syndrome being intensively studied as a putative precursor to AD. MCD does not readily correspond to one of the subtypes of MCI (<xref ref-type="bibr" rid="bibr53-1756285612454323">Petersen, 2011</xref>), and its specific profile merits a separate category. Many differences in fact exist between MCD and MCI (<xref ref-type="table" rid="table5-1756285612454323">Table 5</xref>), and while the understanding of MCD is still preliminary, a syndrome that captures the cognitive effects of white matter dysfunction of any etiology may prove useful in contrast to MCI as a syndrome of gray matter degeneration.</p>
<table-wrap id="table5-1756285612454323" position="float">
<label>Table 5.</label>
<caption><p>Mild cognitive dysfunction compared with mild cognitive impairment.</p></caption>
<graphic alternate-form-of="table5-1756285612454323" xlink:href="10.1177_1756285612454323-table5.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Mild Cognitive Dysfunction</th>
<th align="center">Mild Cognitive Impairment</th>
</tr>
</thead>
<tbody>
<tr>
<td>White matter involvement</td>
<td>Gray matter involvement</td>
</tr>
<tr>
<td>One type</td>
<td>Multiple types</td>
</tr>
<tr>
<td>Clinically and radiologically defined</td>
<td>Clinically defined</td>
</tr>
<tr>
<td>Frontal white matter localization</td>
<td>Hippocampus putative site for amnestic MCI</td>
</tr>
<tr>
<td>Neuroimaging biomarkers available</td>
<td>Biomarkers not firmly established</td>
</tr>
<tr>
<td>Myelin damage with or without axonal loss</td>
<td>Synapse and cell body loss</td>
</tr>
<tr>
<td>Applicable to any age</td>
<td>Applicable only to aging</td>
</tr>
<tr>
<td>Relevant to all white matter disorders</td>
<td>Relevant to neurodegenerative disease</td>
</tr>
<tr>
<td>Treatment of disorder may be effective</td>
<td>No treatment known to be effective</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section5-1756285612454323">
<title>Clinical implications</title>
<p>The clinical impact of WMD and MCD will be apparent in terms of improving diagnosis, prognostication, and treatment options. As in every clinical setting, maintaining suspicion for the problem will improve the likelihood of its detection, and thus improve all further aspects of care.</p>
<p>The diagnosis of cognitive decline related to white matter involvement can be challenging because language is typically normal or nearly so in affected patients, and deficits are more apparent in cognitive speed, executive function, and attention. The relative subtlety of these deficits can mean that many impaired patients remain undetected as other sensorimotor features of the illness often dominate the clinical encounter. Detailed neurobehavioral or neuropsychological evaluation is sensitive to these deficits but may not always be feasible, and so brief clinical measures may be required. The familiar Mini-Mental State Examination (MMSE; <xref ref-type="bibr" rid="bibr27-1756285612454323">Folstein et al., 1975</xref>), while useful in the assessment of AD, is heavily weighted toward language and relatively insensitive to the executive dysfunction of patients with white matter disorders (<xref ref-type="bibr" rid="bibr28-1756285612454323">Franklin et al., 1988</xref>; <xref ref-type="bibr" rid="bibr61-1756285612454323">Swirsky-Sacchetti et al., 1992</xref>). Other more useful tests include the Montreal Cognitive Assessment (MoCA; <xref ref-type="bibr" rid="bibr50-1756285612454323">Nasreddine et al., 2005</xref>), the Frontal Assessment Battery (FAB; <xref ref-type="bibr" rid="bibr13-1756285612454323">Dubois et al., 2000</xref>), and the Clock Drawing Test (CDT; <xref ref-type="bibr" rid="bibr11-1756285612454323">Cosentino et al., 2004</xref>). The MoCA (<xref ref-type="bibr" rid="bibr34-1756285612454323">Griebe et al., 2011</xref>), the FAB (<xref ref-type="bibr" rid="bibr38-1756285612454323">Kanno et al., 2011</xref>), and the CDT (<xref ref-type="bibr" rid="bibr39-1756285612454323">Kim et al., 2009</xref>) have all been found sensitive to white matter dysfunction in various disorders. The MoCA may be most convenient of these measures as it incorporates executive function and clock drawing tasks into a 30-point format; another advantage is that it enables the testing of memory retrieval, a clinical feature central to the assessment of WMD (<xref ref-type="table" rid="table2-1756285612454323">Table 2</xref>).</p>
<p>Determining the prognosis of WMD and MCD will be improved by greater understanding of white matter neurobiology. The wide range of white matter disorders of course means that prognosis depends most critically on the disease, intoxication, or injury present, the age of the patient, and impact of co-existent problems. Generalizations about all white matter disorders, however, are already possible. It is now known, for example, that axonal loss clearly implies a worse prognosis than myelin damage alone (<xref ref-type="bibr" rid="bibr63-1756285612454323">Trapp et al., 1998</xref>; <xref ref-type="bibr" rid="bibr48-1756285612454323">Medana and Esiri, 2003</xref>). In addition, as the MCD construct is applied to white matter disorders at an early stage, an intriguing prospect is the opportunity to use neuroimaging biomarkers together with clinical data to detect dysfunction at a time when the prognosis for recovery is far more favorable (<xref ref-type="bibr" rid="bibr25-1756285612454323">Filley et al., 2009</xref>; <xref ref-type="bibr" rid="bibr40-1756285612454323">Kozora and Filley, 2011</xref>).</p>
<p>Treatment of WMD and MCD is also likely to improve. Each disorder causing these syndromes will be addressed by investigation within the relevant research community, and preventive, medical, surgical, psychiatric, and rehabilitative interventions may all be relevant. Among many questions is whether immunosuppressive and immunomodulatory treatment in MS will effect cognitive improvement, as has been suspected (<xref ref-type="bibr" rid="bibr26-1756285612454323">Fischer et al., 2000</xref>; <xref ref-type="bibr" rid="bibr64-1756285612454323">Tumani and Uttner, 2007</xref>). Other promising therapeutic avenues for white matter disorders include bone marrow transplantation (<xref ref-type="bibr" rid="bibr41-1756285612454323">Krivit et al., 1999</xref>), gene therapy (<xref ref-type="bibr" rid="bibr43-1756285612454323">Leone et al., 2000</xref>), and stem cell therapeutics (<xref ref-type="bibr" rid="bibr32-1756285612454323">Goldman, 2007</xref>; <xref ref-type="bibr" rid="bibr62-1756285612454323">Tran et al., 2010</xref>). An interesting approach to many psychiatric disorders has been proposed with the use of deep brain stimulation (DBS) within white matter structures; DBS was shown effective for intractable depression when applied to the subgenual white matter (<xref ref-type="bibr" rid="bibr45-1756285612454323">Mayberg et al., 2005</xref>) and for obsessive-compulsive disorder after stimulation of the ventral anterior internal capsule (<xref ref-type="bibr" rid="bibr33-1756285612454323">Greenberg et al., 2006</xref>). The rehabilitation of white matter disorders may also be influenced by new understanding of the response to neuropathologic insults. Evidence has been presented that white matter may be reparable by intrinsic plasticity that can remyelinate axonal segments through activity-dependent myelination (<xref ref-type="bibr" rid="bibr66-1756285612454323">Wake, Lee, and Fields, 2011</xref>; see below).</p>
</sec>
<sec id="section6-1756285612454323">
<title>Research perspectives</title>
<p>Many new directions can be imagined from a consideration of the role of white matter in cognition. These include pursuing a better understanding of normal white matter neuroanatomy as it participates in the architecture of cognition, novel innovations for diagnosis and treatment of many dementing disorders, and, perhaps most intriguingly, the hypothesis that AD may in fact begin in the white matter (<xref ref-type="bibr" rid="bibr7-1756285612454323">Bartzokis, 2011</xref>).</p>
<p>An important outcome of work on myelinated systems is that the normal white matter will be much better understood. In recent years, classic neuroanatomy has been greatly advanced by more detailed understanding of the origin, course, and termination of white matter tracts in the rhesus monkey (<xref ref-type="bibr" rid="bibr57-1756285612454323">Schmahmann and Pandya, 2006</xref>), and new neuroimaging methods promise to address these questions in humans with increasing sophistication. A productive collaboration can be developed between neuroimaging and traditional neuroanatomy to refine knowledge of normal white matter (<xref ref-type="bibr" rid="bibr57-1756285612454323">Schmahmann and Pandya, 2006</xref>; <xref ref-type="bibr" rid="bibr49-1756285612454323">Mesulam, 2011</xref>).</p>
<p>These investigations will in turn clarify the neuroanatomy of distributed neural networks, the central organizational feature of the brain as it subserves the wide array of cognitive and emotional operations comprising the human behavioral repertoire. White matter is the connecting tissue between cortical and subcortical gray matter regions within and between the hemispheres, and recent data also point to the importance of white matter in networks involving the cerebellum (<xref ref-type="bibr" rid="bibr58-1756285612454323">Schmahmann and Pandya, 2008</xref>). The concept of the connectome – “a comprehensive structural description of the network of elements and connections forming the human brain” – has recently been proposed to capture the spirit of this endeavor (<xref ref-type="bibr" rid="bibr60-1756285612454323">Sporns, 2011</xref>), and mapping of human brain connectivity is underway.</p>
<p>A fascinating new idea is the notion of white matter plasticity. Long known to be a capacity of gray matter related to synaptic function, plasticity has recently been observed to occur in white matter as well (<xref ref-type="bibr" rid="bibr14-1756285612454323">Fields, 2010</xref>). This phenomenon has been demonstrated in both normal individuals, such as piano players whose pyramidal tract integrity correlated with number of hours practiced (<xref ref-type="bibr" rid="bibr9-1756285612454323">Bengtsson et al., 2005</xref>), and in neurologic patients, such as those with Broca’s aphasia in whom the right arcuate fasciculus volume increased as Melodic Intonation Therapy improved language performance (<xref ref-type="bibr" rid="bibr56-1756285612454323">Schlaug et al, 2009</xref>). White matter plasticity may be mediated by newly discovered glutamatergic axo-oligodendroglial synapses within white matter, which appear to be capable of myelinating distal axonal segments upon stimulation of the proximal axon (<xref ref-type="bibr" rid="bibr4-1756285612454323">Alix and Domingues, 2011</xref>). More study is needed to understand the potential applications of white matter plasticity to clinical populations, but the implications for recovery after any myelin lesion may be profound.</p>
<p>The possibility exists that AD may originate in cerebral white matter (<xref ref-type="bibr" rid="bibr7-1756285612454323">Bartzokis, 2011</xref>). This “myelin hypothesis” posits that the vulnerability of aging myelin to a host of insults such as ischemia, trauma, and iron toxicity may initiate a cascade of events culminating in dementia; plaque and tangle formation are interpreted not as primary events, but instead as markers of failed myelin repair processes (<xref ref-type="bibr" rid="bibr7-1756285612454323">Bartzokis, 2011</xref>) This novel idea merits attention given the still uncertain etiopathogenesis of AD, and the failure of amyloid-targeted immunotherapies to effect improvement in dementia that have raised doubts about the amyloid hypothesis (<xref ref-type="bibr" rid="bibr35-1756285612454323">Hardy, 2009</xref>). Much work is needed to evaluate the myelin hypothesis, but provocative neuroimaging studies have found evidence of microstructural white matter damage in women genetically at risk for AD before the onset of dementia and the appearance of medial temporal atrophy (<xref ref-type="bibr" rid="bibr31-1756285612454323">Gold et al., 2010</xref>).</p>
</sec>
<sec id="section7-1756285612454323">
<title>Summary</title>
<p>The syndrome of WMD has now existed for more than 20 years, and its utility as an organizational concept appears to be expanding. WMD, and its more recent companion MCD, are not disease-specific diagnoses, and neither incidence nor prevalence data are available for either syndrome, but steadily mounting evidence for the role of white matter in cognition helps support their legitimacy. As a measure of how much this field has grown since the coining of the term WMD (<xref ref-type="bibr" rid="bibr19-1756285612454323">Filley et al., 1988</xref>), a basic <email>Medline@Ovid</email> search discloses that the term “white matter dementia” brought up only 96 citations from 1860 through 1987, while 8860 citations appeared from 1988 through 2011. White matter is clearly receiving more attention in the study of dementia.</p>
<p>The clinical and research benefits of investigating WMD may be substantial. The diagnosis of many patients with white matter disorders affecting cognition can be enhanced, particularly if the putative precursor syndrome of MCD proves useful in identifying those with early involvement. Treatment involving existing and many evolving modalities will continue to advance, and the opportunity to treat patients at the early stage of MCD may substantially improve outcome. Research will be invigorated by a host of innovations that consider the white matter as the primary site of neuropathology.</p>
<p>Finally, from a theoretical perspective, the study of white matter and cognition offers the appealing prospect of furthering the pursuit of fundamental brain-behavior relationships. It is commonly held that basic science necessarily involves reductionistic investigation in the laboratory, where a tightly defined problem can be isolated, described, and modeled as a basis for understanding a larger system. But when the larger system is the vast panoply of human behavior, humans must be the objects of investigation (<xref ref-type="bibr" rid="bibr8-1756285612454323">Bear, 1997</xref>), and it is critical to understand the cerebral origins of behavioral dysfunction by assembling the sequelae of structural damage from many disorders, and then seeking to combine these data into a clinical syndrome with wide generalizability. Cataloguing and synthesizing the cognitive effects of white matter dysfunction can thus be seen as basic science as much as examining the impact of a gene mutation, viral infection, or inflammatory cascade. Consideration of the contributions of white matter to cognition and its decline significantly expands the fundamental study of human mentation that is the essence of behavioral neurology.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This work was in part supported by two research grants: 1 R01 AR04915-01A2 8/15/04-6/30/08 National Institute for Arthritis, Musculoskeletal and Skin Disease MRI/MRS Correlates of Cognitive Function in Systemic Lupus Erythematosus 3 RO1 AR049152-02S1 7/1/05-6/30/08 National Institute for Arthritis, Musculoskeletal and Skin Disease Immune Correlates of Cognitive Function in Systemic Lupus Erythematosus.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Absinta</surname><given-names>M.</given-names></name>
<name><surname>Rocca</surname><given-names>M.A.</given-names></name>
<name><surname>Moiola</surname><given-names>L.</given-names></name>
<name><surname>Copetti</surname><given-names>M.</given-names></name>
<name><surname>Milani</surname><given-names>N.</given-names></name>
<name><surname>Falini</surname><given-names>A.</given-names></name>
<etal/></person-group>. (<year>2011</year>) <article-title>Cortical lesions in children with multiple sclerosis</article-title>. <source>Neurology</source> <volume>76</volume>: <fpage>910</fpage>–<lpage>913</lpage>.</citation>
</ref>
<ref id="bibr2-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Albert</surname><given-names>M.L.</given-names></name>
<name><surname>Feldman</surname><given-names>R.G.</given-names></name>
<name><surname>Willis</surname><given-names>A.L.</given-names></name>
</person-group> (<year>1974</year>) <article-title>The ‘subcortical dementia’ of progressive supranuclear palsy</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <volume>37</volume>: <fpage>121</fpage>–<lpage>130</lpage>.</citation>
</ref>
<ref id="bibr3-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Al-Hajri</surname><given-names>Z.</given-names></name>
<name><surname>Del Bigio</surname><given-names>M.R.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Brain damage in a large cohort of solvent abusers</article-title>. <source>Acta Neuropathol</source> <volume>119</volume>: <fpage>435</fpage>–<lpage>445</lpage>.</citation>
</ref>
<ref id="bibr4-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alix</surname><given-names>J.J.</given-names></name>
<name><surname>Domingues</surname><given-names>A.M.</given-names></name>
</person-group> (<year>2011</year>) <article-title>White matter synapses: form, function, and dysfunction</article-title>. <source>Neurology</source> <volume>76</volume>: <fpage>397</fpage>– <lpage>404</lpage>.</citation>
</ref>
<ref id="bibr5-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Amato</surname><given-names>M.P.</given-names></name>
<name><surname>Portaccio</surname><given-names>E.</given-names></name>
<name><surname>Goretti</surname><given-names>B.</given-names></name>
<name><surname>Zipoli</surname><given-names>V.</given-names></name>
<name><surname>Iudice</surname><given-names>A.</given-names></name>
<name><surname>Della Pina</surname><given-names>D.</given-names></name>
<etal/></person-group>. (<year>2010</year>) <article-title>Relevance of cognitive deterioration in early relapsing-remitting MS: a 3-year follow-up study</article-title>. <source>Mult Scler</source> <volume>16</volume>: <fpage>1474</fpage>–<lpage>1482</lpage>.</citation>
</ref>
<ref id="bibr6-1756285612454323">
<citation citation-type="book"><collab>American Psychiatric Association</collab> (<year>1994</year>). <article-title>Diagnostic and Statistical Manual</article-title>. <edition>4th ed</edition>. <publisher-name>American Psychiatric Association Press</publisher-name>: <publisher-loc>Washington, D.C</publisher-loc>.</citation>
</ref>
<ref id="bibr7-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bartzokis</surname><given-names>G.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Alzheimer’s disease as homeostatic responses to age-related myelin breakdown</article-title>. <source>Neurobiol Aging</source> <volume>32</volume>: <fpage>1341</fpage>–<lpage>1371</lpage></citation>
</ref>
<ref id="bibr8-1756285612454323">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Bear</surname><given-names>D.M.</given-names></name>
</person-group> (<year>1997</year>) <article-title>Interictal behavior in temporal lobe epilepsy</article-title>. In <person-group person-group-type="editor">
<name><surname>Schacter</surname><given-names>S.</given-names></name>
<name><surname>Devinsky</surname><given-names>O.</given-names></name>
</person-group> (eds.) <article-title>Behavioral neurology and the legacy of Norman Geschwind</article-title>. <publisher-name>Lippincott-Raven</publisher-name>: <publisher-loc>Philadelphia</publisher-loc>.</citation>
</ref>
<ref id="bibr9-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bengtsson</surname><given-names>S.L.</given-names></name>
<name><surname>Nagy</surname><given-names>Z.</given-names></name>
<name><surname>Skare</surname><given-names>S.</given-names></name>
<name><surname>Forsman</surname><given-names>L.</given-names></name>
<name><surname>Forssberg</surname><given-names>H.</given-names></name>
<name><surname>Ullén</surname><given-names>F.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Extensive piano practicing has regionally specific effects on white matter development</article-title>. <source>Nat Neurosci</source> <volume>8</volume>: <fpage>1148</fpage>–<lpage>1150</lpage></citation>
</ref>
<ref id="bibr10-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bonelli</surname><given-names>R.M.</given-names></name>
<name><surname>Cummings</surname><given-names>J.L.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Frontal-subcortical dementias</article-title>. <source>Neurologist</source> <volume>14</volume>: <fpage>100</fpage>–<lpage>107</lpage>.</citation>
</ref>
<ref id="bibr11-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cosentino</surname><given-names>S.</given-names></name>
<name><surname>Jefferson</surname><given-names>A.</given-names></name>
<name><surname>Chute</surname><given-names>D.L.</given-names></name>
<name><surname>Kaplan</surname><given-names>E.</given-names></name>
<name><surname>Libon</surname><given-names>D.J.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Clock drawing errors in dementia: neuropsychological and neuroanatomical considerations</article-title>. <source>Cogn Behav Neurol</source> <volume>17</volume>: <fpage>74</fpage>–<lpage>84</lpage>.</citation>
</ref>
<ref id="bibr12-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Debette</surname><given-names>S.</given-names></name>
<name><surname>Markus</surname><given-names>H.S.</given-names></name>
</person-group> (<year>2010</year>) <article-title>The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis</article-title>. <source>BMJ</source> <volume>26</volume>; <issue>341</issue>: <fpage>c3666</fpage></citation>
</ref>
<ref id="bibr13-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dubois</surname><given-names>B.</given-names></name>
<name><surname>Slachevsky</surname><given-names>A.</given-names></name>
<name><surname>Litvan</surname><given-names>I</given-names></name>
<name><surname>Pillon</surname><given-names>B.</given-names></name>
</person-group> (<year>2000</year>) <article-title>The FAB: a Frontal Assessment Battery at bedside</article-title>. <source>Neurology</source> <volume>55</volume>: <fpage>1621</fpage>–<lpage>1626</lpage>.</citation>
</ref>
<ref id="bibr14-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fields</surname><given-names>R.D.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Neuroscience. Change in the brain’s white matter</article-title>. <source>Science</source> <volume>330</volume>: <fpage>768</fpage>–<lpage>769</lpage>.</citation>
</ref>
<ref id="bibr15-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Filley</surname><given-names>C.M.</given-names></name>
</person-group> (<year>2010</year>) <article-title>White matter: organization and functional relevance</article-title>. <source>Neuropsychol Rev</source> <volume>20</volume>: <fpage>158</fpage>–<lpage>173</lpage>.</citation>
</ref>
<ref id="bibr16-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Filley</surname><given-names>C.M.</given-names></name>
</person-group> (<year>2011a</year>) <article-title>White matter: beyond focal disconnection</article-title>. <source>Neurol Clin</source> <volume>29</volume>: <fpage>81</fpage>–<lpage>97</lpage>.</citation>
</ref>
<ref id="bibr17-1756285612454323">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Filley</surname><given-names>C.M.</given-names></name>
</person-group> (<year>2011b</year>) <article-title>Neurobehavioral anatomy</article-title>, <edition>3nd ed</edition>. <publisher-name>University Press of Colorado</publisher-name>: <publisher-loc>Boulder, CO</publisher-loc>.</citation>
</ref>
<ref id="bibr18-1756285612454323">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Filley</surname><given-names>C.M.</given-names></name>
</person-group> (<year>2012</year>) <article-title>The behavioral neurology of white matter</article-title>. <edition>2nd ed</edition>. <publisher-name>Oxford University Press</publisher-name>: <publisher-loc>New York</publisher-loc>.</citation>
</ref>
<ref id="bibr19-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Filley</surname><given-names>C.M.</given-names></name>
<name><surname>Franklin</surname><given-names>G.M.</given-names></name>
<name><surname>Heaton</surname><given-names>R.K.</given-names></name>
<name><surname>Rosenberg</surname><given-names>N.L.</given-names></name>
</person-group> (<year>1988</year>) <article-title>White matter dementia: clinical disorders and implications</article-title>. <source>Neuropsychiatry Neuropsychol Behav Neurol</source> <volume>1</volume>: <fpage>239</fpage>–<lpage>254</lpage>.</citation>
</ref>
<ref id="bibr20-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Filley</surname><given-names>C.M.</given-names></name>
<name><surname>Heaton</surname><given-names>R.K.</given-names></name>
<name><surname>Rosenberg</surname><given-names>N.L</given-names></name>
</person-group> (<year>1990</year>) <article-title>White matter dementia in chronic toluene abuse</article-title>. <source>Neurology</source> <volume>40</volume>: <fpage>532</fpage>–<lpage>534</lpage>.</citation>
</ref>
<ref id="bibr21-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Filley</surname><given-names>C.M.</given-names></name>
<name><surname>Heaton</surname><given-names>R.K.</given-names></name>
<name><surname>Nelson</surname><given-names>L.M.</given-names></name>
<name><surname>Burks</surname><given-names>J.S.</given-names></name>
<name><surname>Franklin</surname><given-names>G.M.</given-names></name>
</person-group> (<year>1989</year>) <article-title>A comparison of dementia in Alzheimer’s Disease and multiple sclerosis</article-title>. <source>Arch Neurol</source> <volume>46</volume>: <fpage>157</fpage>–<lpage>161</lpage>.</citation>
</ref>
<ref id="bibr22-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Filley</surname><given-names>C.M.</given-names></name>
</person-group> (<year>1998</year>) <article-title>The behavioral neurology of cerebral white matter</article-title>. <source>Neurology</source> <volume>50</volume>: <fpage>1535</fpage>–<lpage>1540</lpage>.</citation>
</ref>
<ref id="bibr23-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Filley</surname><given-names>C.M.</given-names></name>
<name><surname>Kleinschmidt-DeMasters</surname><given-names>B.K.</given-names></name>
</person-group> (<year>2001</year>) <article-title>Toxic leukoencephalopathy</article-title>. <source>N Engl J Med</source> <volume>345</volume>: <fpage>425</fpage>–<lpage>432</lpage>.</citation>
</ref>
<ref id="bibr24-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Filley</surname><given-names>C.M.</given-names></name>
<name><surname>Halliday</surname><given-names>W.</given-names></name>
<name><surname>Kleinschmidt-DeMasters</surname><given-names>B.K.</given-names></name>
</person-group> (<year>2004</year>) <article-title>The effects of toluene on the central nervous system</article-title>. <source>J Neuropathol Exp Neurol</source> <volume>63</volume>: <fpage>1</fpage>–<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr25-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Filley</surname><given-names>C.M.</given-names></name>
<name><surname>Kozora</surname><given-names>E.</given-names></name>
<name><surname>Brown</surname><given-names>M.S.</given-names></name>
<name><surname>Miller</surname><given-names>D.E.</given-names></name>
<name><surname>West</surname><given-names>S.G.</given-names></name>
<name><surname>Arciniegas</surname><given-names>D.B.</given-names></name>
<etal/></person-group>. (<year>2009</year>) <article-title>White matter microstructure and cognition in non-neuropsychiatric systemic lupus erythematosus</article-title>. <source>Cogn Behav Neurol</source> <volume>22</volume>: <fpage>38</fpage>–<lpage>44</lpage>.</citation>
</ref>
<ref id="bibr26-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fischer</surname><given-names>J.S.</given-names></name>
<name><surname>Priore</surname><given-names>R.L.</given-names></name>
<name><surname>Jacobs</surname><given-names>L.D.</given-names></name>
<name><surname>Cookfair</surname><given-names>D.L.</given-names></name>
<name><surname>Rudick</surname><given-names>R.A.</given-names></name>
<name><surname>Herndon</surname><given-names>R,M.</given-names></name>
<etal/></person-group> (<year>2000</year>) <article-title>Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group</article-title>. <source>Ann Neurol</source> <volume>48</volume>: <fpage>885</fpage>–<lpage>892</lpage>.</citation>
</ref>
<ref id="bibr27-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Folstein</surname><given-names>M.F.</given-names></name>
<name><surname>Folstein</surname><given-names>S.E.</given-names></name>
<name><surname>McHugh</surname><given-names>P.R.</given-names></name>
</person-group>(<year>1975</year>) <article-title>"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician</article-title>. <source>J Psychiatr Res</source> <volume>12</volume>: <fpage>189</fpage>–<lpage>198</lpage>.</citation>
</ref>
<ref id="bibr28-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Franklin</surname><given-names>G.M.</given-names></name>
<name><surname>Heaton</surname><given-names>R.K.</given-names></name>
<name><surname>Nelson</surname><given-names>L.M.</given-names></name>
<name><surname>Filley</surname><given-names>C.M.</given-names></name>
<name><surname>Seibert</surname><given-names>C.</given-names></name>
</person-group> (<year>1988</year>) <article-title>Correlation of neuropsychological and MRI findings in chronic/progressive multiple sclerosis</article-title>. <source>Neurology</source> <volume>38</volume>: <fpage>1826</fpage>–<lpage>1829</lpage>.</citation>
</ref>
<ref id="bibr29-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Franklin</surname><given-names>G.M.</given-names></name>
<name><surname>Nelson</surname><given-names>L.M.</given-names></name>
<name><surname>Filley</surname><given-names>C.M.</given-names></name>
<name><surname>Heaton</surname><given-names>R.K.</given-names></name>
</person-group> (<year>1989</year>) <article-title>Cognitive loss in multiple sclerosis. Case reports and review of the literature</article-title>. <source>Arch Neurol</source> <volume>46</volume>: <fpage>162</fpage>–<lpage>167</lpage>.</citation>
</ref>
<ref id="bibr30-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Geschwind</surname><given-names>N.</given-names></name>
</person-group> (<year>1965</year>) <article-title>Disconnexion syndromes in animals and man</article-title>. <source>Brain</source> <volume>88</volume>: <fpage>237</fpage>-<lpage>294</lpage>, <fpage>585</fpage>–<lpage>644</lpage>.</citation>
</ref>
<ref id="bibr31-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gold</surname><given-names>B.T.</given-names></name>
<name><surname>Powell</surname><given-names>D.K.</given-names></name>
<name><surname>Andersen</surname><given-names>A.H.</given-names></name>
<name><surname>Smith</surname><given-names>C.D.</given-names></name>
</person-group>(<year>2010</year>) <article-title>Alterations in multiple measures of white matter integrity in normal women at high risk for Alzheimer’s disease</article-title>. <source>Neuroimage</source> <volume>52</volume>: <fpage>1487</fpage>–<lpage>1494</lpage>.</citation>
</ref>
<ref id="bibr32-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goldman</surname><given-names>S.A.</given-names></name>
</person-group> (<year>2007</year>) .<article-title>Disease targets and strategies for the therapeutic modulation of endogenous neural stem and progenitor cells</article-title>. <source>Clin Pharmacol Ther</source> <volume>82</volume>: <fpage>453</fpage>–<lpage>460</lpage>.</citation>
</ref>
<ref id="bibr33-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Greenberg</surname><given-names>B.D.</given-names></name>
<name><surname>Malone</surname><given-names>D.A.</given-names></name>
<name><surname>Friehs</surname><given-names>G.M</given-names></name>
<name><surname>Rezai</surname><given-names>A.R.</given-names></name>
<name><surname>Kubu</surname><given-names>C.S.</given-names></name>
<name><surname>Malloy</surname><given-names>P.F.</given-names></name>
<etal/></person-group>. (<year>2006</year>) <article-title>Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder</article-title>. <source>Neuropsychopharmacology</source> <volume>31</volume>: <fpage>2384</fpage>–<lpage>2393</lpage>.</citation>
</ref>
<ref id="bibr34-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Griebe</surname><given-names>M.</given-names></name>
<name><surname>Förster</surname><given-names>A.</given-names></name>
<name><surname>Wessa</surname><given-names>M.</given-names></name>
<name><surname>Rossmanith</surname><given-names>C.</given-names></name>
<name><surname>Bäzner</surname><given-names>H.</given-names></name>
<name><surname>Sauer</surname><given-names>T.</given-names></name>
<etal/></person-group>. (<year>2011</year>) <article-title>Loss of callosal fibre integrity in healthy elderly with age-related white matter changes</article-title>. <source>J Neurol</source> <volume>258</volume>: <fpage>1451</fpage>–<lpage>1459</lpage>.</citation>
</ref>
<ref id="bibr35-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hardy</surname><given-names>J.</given-names></name>
</person-group> (<year>2009</year>) <article-title>The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal</article-title>. <source>J Neurochem</source> <volume>10</volume>: <fpage>1129</fpage>–<lpage>1134</lpage>.</citation>
</ref>
<ref id="bibr36-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hormes</surname><given-names>J.T.</given-names></name>
<name><surname>Filley</surname><given-names>C.M</given-names></name>
<name><surname>Rosenberg</surname><given-names>N.L.</given-names></name>
</person-group> (<year>1986</year>) <article-title>Neurologic sequelae of chronic solvent vapor abuse</article-title>. <source>Neurology</source> <volume>36</volume>: <fpage>698</fpage>–<lpage>702</lpage>.</citation>
</ref>
<ref id="bibr37-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Inzitari</surname><given-names>D.</given-names></name>
<name><surname>Pracucci</surname><given-names>G.</given-names></name>
<name><surname>Poggesi</surname><given-names>A.</given-names></name>
<name><surname>Carlucci</surname><given-names>G.</given-names></name>
<name><surname>Barkhof</surname><given-names>F.</given-names></name>
<name><surname>Chabriat</surname><given-names>H.</given-names></name>
<etal/></person-group>. (<year>2009</year>) <article-title>Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (leukoaraiosis and disability) study cohort</article-title>. <source>BMJ</source> <volume>6</volume>; <issue>339</issue>: <fpage>b2477</fpage></citation>
</ref>
<ref id="bibr38-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kanno</surname><given-names>S.</given-names></name>
<name><surname>Abe</surname><given-names>N.</given-names></name>
<name><surname>Saito</surname><given-names>M.</given-names></name>
<name><surname>Takagi</surname><given-names>M.</given-names></name>
<name><surname>Nishio</surname><given-names>Y.</given-names></name>
<name><surname>Hayashi</surname><given-names>A.</given-names></name>
<etal/></person-group>. (<year>2011</year>) <article-title>White matter involvement in idiopathic normal pressure hydrocephalus: a voxel-based diffusion tensor imaging study</article-title>. <source>J Neurol</source> <volume>258</volume>: <fpage>1949</fpage>–<lpage>1957</lpage>.</citation>
</ref>
<ref id="bibr39-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>Y.S.</given-names></name>
<name><surname>Lee</surname><given-names>K.M</given-names></name>
<name><surname>Choi</surname><given-names>B.H.</given-names></name>
<name><surname>Sohn</surname><given-names>E.H.</given-names></name>
<name><surname>Lee</surname><given-names>A.Y.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Relation between the clock drawing test (CDT) and structural changes of brain in dementia</article-title>. <source>Arch Gerontol Geriatr</source> <volume>48</volume>: <fpage>218</fpage>–<lpage>221</lpage>.</citation>
</ref>
<ref id="bibr40-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kozora</surname><given-names>E.</given-names></name>
<name><surname>Filley</surname><given-names>C.M.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Cognitive dysfunction and white matter abnormalities in systemic lupus erythematosus</article-title>. <source>J Int Neuropsychol Soc</source>; <volume>17</volume>: <fpage>1</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr41-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Krivit</surname><given-names>W.</given-names></name>
<name><surname>Peters</surname><given-names>C.</given-names></name>
<name><surname>Shapiro</surname><given-names>E.G.</given-names></name>
</person-group> (<year>1999</year>) <article-title>Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III</article-title>. <source>Curr Opin Neurol</source> <volume>12</volume>: <fpage>167</fpage>–<lpage>176</lpage>.</citation>
</ref>
<ref id="bibr42-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lafosse</surname><given-names>J.M.</given-names></name>
<name><surname>Corboy</surname><given-names>J.R.</given-names></name>
<name><surname>Leehey</surname><given-names>M.A.</given-names></name>
<name><surname>Seeberger</surname><given-names>L.C.</given-names></name>
<name><surname>Filley</surname><given-names>C.M.</given-names></name>
</person-group> (<year>2007</year>) <article-title>MS vs. HD: Can white matter and subcortical gray matter pathology be distinguished neuropsychologically?</article-title> <source>J Clin Exp Neuropsychol</source> <volume>29</volume>: <fpage>142</fpage>–<lpage>154</lpage>.</citation>
</ref>
<ref id="bibr43-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leone</surname><given-names>P.</given-names></name>
<name><surname>Janson</surname><given-names>C.G.</given-names></name>
<name><surname>Bilianuk</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Sorgi</surname><given-names>F.</given-names></name>
<name><surname>Huang</surname><given-names>L.</given-names></name>
<etal/></person-group> (<year>2000</year>) <article-title>Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan’s disease</article-title>. <source>Ann Neurol</source> <volume>48</volume>: <fpage>27</fpage>–<lpage>38</lpage>.</citation>
</ref>
<ref id="bibr44-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lucchinetti</surname><given-names>C.F.</given-names></name>
<name><surname>Popescu</surname><given-names>B.F.</given-names></name>
<name><surname>Bunyan</surname><given-names>R.F.</given-names></name>
<name><surname>Moll</surname><given-names>N.M.</given-names></name>
<name><surname>Roemer</surname><given-names>S.F.</given-names></name>
<name><surname>Lassmann</surname><given-names>H.</given-names></name>
<etal/></person-group>. (<year>2011</year>). <article-title>Inflammatory cortical demyelination in early multiple sclerosis</article-title>. <source>N Engl J Med</source> <volume>365</volume>: <fpage>2188</fpage>–<lpage>2197</lpage>.</citation>
</ref>
<ref id="bibr45-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mayberg</surname><given-names>H.S.</given-names></name>
<name><surname>Lozano</surname><given-names>A.M.</given-names></name>
<name><surname>Voon</surname><given-names>V.</given-names></name>
<name><surname>McNeely</surname><given-names>H.E.</given-names></name>
<name><surname>Seminowicz</surname><given-names>D.</given-names></name>
<name><surname>Hamani</surname><given-names>C.</given-names></name>
<etal/></person-group>. (<year>2005</year>) <article-title>Deep brain stimulation for treatment-resistant depression</article-title>. <source>Neuron</source> <volume>45</volume>: <fpage>651</fpage>–<lpage>660</lpage>.</citation>
</ref>
<ref id="bibr46-1756285612454323">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>McHugh</surname><given-names>P.R.</given-names></name>
<name><surname>Folstein</surname><given-names>M.F.</given-names></name>
</person-group> (<year>1975</year>) <article-title>Psychiatric syndromes of Huntington’s Chorea</article-title>. In: <person-group person-group-type="editor">
<name><surname>Benson</surname><given-names>D.F.</given-names></name>
<name><surname>Blumer</surname><given-names>D.</given-names></name>
</person-group> (eds.) <source>Psychiatric aspects of neurologic disease</source>, <volume>vol. 1</volume>. <publisher-name>Grune and Stratton</publisher-name>: <publisher-loc>New York</publisher-loc>.</citation>
</ref>
<ref id="bibr47-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McKhann</surname><given-names>G.</given-names></name>
<name><surname>Drachman</surname><given-names>D.</given-names></name>
<name><surname>Folstein</surname><given-names>M.</given-names></name>
<name><surname>Katzman</surname><given-names>R.</given-names></name>
<name><surname>Price</surname><given-names>D.</given-names></name>
<name><surname>Stadlan</surname><given-names>E.M.</given-names></name>
</person-group> (<year>1984</year>) <article-title>Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease</article-title>. <source>Neurology</source> <volume>34</volume>: <fpage>939</fpage>–<lpage>944</lpage>.</citation>
</ref>
<ref id="bibr48-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Medana</surname><given-names>I.M.</given-names></name>
<name><surname>Esiri</surname><given-names>M.M.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Axonal damage: a key predictor of outcome in human CNS diseases</article-title>. <source>Brain</source> <volume>26</volume>: <fpage>515</fpage>–<lpage>530</lpage>.</citation>
</ref>
<ref id="bibr49-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mesulam</surname><given-names>M</given-names></name>
</person-group>. (<year>2011</year>) <article-title>The evolving landscape of human cortical connectivity: Facts and inferences</article-title>. <source>Neuroimage</source> <month>Dec</month> <day>22</day> [<comment>Epub ahead of print</comment>]</citation>
</ref>
<ref id="bibr50-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nasreddine</surname><given-names>Z.S.</given-names></name>
<name><surname>Phillips</surname><given-names>N.A.</given-names></name>
<name><surname>Bédirian</surname><given-names>V.</given-names></name>
<name><surname>Charbonneau</surname><given-names>S.</given-names></name>
<name><surname>Whitehead</surname><given-names>V.</given-names></name>
<name><surname>Collin</surname><given-names>I.</given-names></name>
<etal/></person-group>. (<year>2005</year>) <article-title>The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment</article-title>. <source>J Am Geriatr Soc</source> <volume>53</volume>: <fpage>695</fpage>–<lpage>699</lpage>.</citation>
</ref>
<ref id="bibr51-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Parvizi</surname><given-names>J.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Corticocentric myopia: old bias in new cognitive sciences</article-title>. <source>Trends Cogn Sci</source> <volume>13</volume>: <fpage>354</fpage>–<lpage>359</lpage>.</citation>
</ref>
<ref id="bibr52-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Penke</surname><given-names>L.</given-names></name>
<name><surname>Muñoz Maniega</surname><given-names>S.</given-names></name>
<name><surname>Murray</surname><given-names>C.</given-names></name>
<name><surname>Gow</surname><given-names>A.J.</given-names></name>
<name><surname>Hernández</surname><given-names>M.C.</given-names></name>
<name><surname>Clayden</surname><given-names>J.D.</given-names></name>
<etal/></person-group>. (<year>2010</year>) <article-title>A general factor of brain white matter integrity predicts information processing speed in healthy older people</article-title>. <source>J Neurosci</source> <volume>30</volume>: <fpage>7569</fpage>–<lpage>7574</lpage>.</citation>
</ref>
<ref id="bibr53-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Petersen</surname><given-names>R.C.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Clinical practice. Mild cognitive impairment</article-title>. <source>N Engl J Med</source> <volume>364</volume>: <fpage>2227</fpage>–<lpage>2234</lpage>.</citation>
</ref>
<ref id="bibr54-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Querfurth</surname><given-names>H.W.</given-names></name>
<name><surname>LaFerla</surname><given-names>F.M.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Alzheimer’s disease</article-title>. <source>N Engl J Med</source> <volume>362</volume>: <fpage>329</fpage>–<lpage>344</lpage>.</citation>
</ref>
<ref id="bibr55-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rosenberg</surname><given-names>N.L.</given-names></name>
<name><surname>Kleinschmidt-DeMasters</surname><given-names>B.K.</given-names></name>
<name><surname>Davis</surname><given-names>K.A.</given-names></name>
<name><surname>Dreisbach</surname><given-names>J.N.</given-names></name>
<name><surname>Hormes</surname><given-names>J.T.</given-names></name>
<name><surname>Filley</surname><given-names>C.M.</given-names></name>
</person-group> (<year>1988</year>) <article-title>Toluene abuse causes diffuse central nervous system white matter changes</article-title>. <source>Ann Neurol</source> <volume>23</volume>: <fpage>611</fpage>–<lpage>614</lpage>.</citation>
</ref>
<ref id="bibr56-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schlaug</surname><given-names>G.</given-names></name>
<name><surname>Marchina</surname><given-names>S.</given-names></name>
<name><surname>Norton</surname><given-names>A.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Evidence for plasticity in white-matter tracts of patients with chronic Broca’s aphasia undergoing intense intonation-based speech therapy</article-title>. <source>Ann N Y Acad Sci</source> <volume>1169</volume>: <fpage>385</fpage>–<lpage>394</lpage>.</citation>
</ref>
<ref id="bibr57-1756285612454323">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Schmahmann</surname><given-names>J.D.</given-names></name>
<name><surname>Pandya</surname><given-names>D.N.</given-names></name>
</person-group> (<year>2006</year>). <article-title>Fiber pathways of the brain</article-title>. <publisher-name>Oxford University Press</publisher-name>: <publisher-loc>New York</publisher-loc>.</citation>
</ref>
<ref id="bibr58-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schmahmann</surname><given-names>J.D.</given-names></name>
<name><surname>Pandya</surname><given-names>D.N.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Disconnection syndromes of basal ganglia, thalamus, and cerebrocerebellar systems</article-title>. <source>Cortex</source> <volume>44</volume>: <fpage>1037</fpage>–<lpage>1066</lpage></citation>
</ref>
<ref id="bibr59-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schmahmann</surname><given-names>J.D.</given-names></name>
<name><surname>Smith</surname><given-names>E.E.</given-names></name>
<name><surname>Eichler</surname><given-names>F.S.</given-names></name>
<name><surname>Filley</surname><given-names>C.M.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Cerebral white matter: neuroanatomy, clinical neurology, and neurobehavioral correlates</article-title>. <source>Ann NY Acad Sci</source> <volume>1142</volume>: <fpage>266</fpage>–<lpage>309</lpage>.</citation>
</ref>
<ref id="bibr60-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sporns</surname><given-names>O.</given-names></name>
</person-group> (<year>2011</year>) <article-title>The human connectome: a complex network</article-title>. <source>Ann N Y Acad Sci</source> <volume>1224</volume>:</citation>
</ref>
<ref id="bibr61-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Swirsky-Sacchetti</surname><given-names>T.</given-names></name>
<name><surname>Field</surname><given-names>H.L.</given-names></name>
<name><surname>Mitchell</surname><given-names>D.R.</given-names></name>
<name><surname>Seward</surname><given-names>J</given-names></name>
<name><surname>Lublin</surname><given-names>F.D.</given-names></name>
<name><surname>Knobler</surname><given-names>R.L.</given-names></name>
<etal/></person-group>. (<year>1992</year>) <article-title>The sensitivity of the Mini-Mental State Exam in the white matter dementia of multiple sclerosis</article-title>. <source>J Clin Psychol</source> <volume>48</volume>: <fpage>779</fpage>–<lpage>786</lpage>.</citation>
</ref>
<ref id="bibr62-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tran</surname><given-names>K.D.</given-names></name>
<name><surname>Ho</surname><given-names>A.</given-names></name>
<name><surname>Jandial</surname><given-names>R.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Stem cell transplantation methods</article-title>. <source>Adv Exp Med Biol</source> <volume>671</volume>: <fpage>41</fpage>–<lpage>57</lpage>.</citation>
</ref>
<ref id="bibr63-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Trapp</surname><given-names>B.D.</given-names></name>
<name><surname>Peterson</surname><given-names>J.</given-names></name>
<name><surname>Ransohoff</surname><given-names>R.M.</given-names></name>
<name><surname>Rudick</surname><given-names>R.</given-names></name>
<name><surname>Mörk</surname><given-names>S.</given-names></name>
<name><surname>Bö</surname><given-names>L.</given-names></name>
</person-group> (<year>1998</year>) <article-title>Axonal transection in the lesions of multiple sclerosis</article-title>. <source>N Engl J Med</source> <volume>338</volume>: <fpage>278</fpage>–<lpage>285</lpage>.</citation>
</ref>
<ref id="bibr64-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tumani</surname><given-names>H.</given-names></name>
<name><surname>Uttner</surname><given-names>I.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Influences on cognition by immunosuppression and immunomodulation in multiple sclerosis</article-title>. <source>J Neurol</source> <volume>254</volume> <supplement>Suppl 2</supplement>: <fpage>II69</fpage>–<lpage>72</lpage>.</citation>
</ref>
<ref id="bibr65-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Turken</surname><given-names>A.</given-names></name>
<name><surname>Whitfield-Gabrieli</surname><given-names>S.</given-names></name>
<name><surname>Bammer</surname><given-names>R.</given-names></name>
<name><surname>Baldo</surname><given-names>J.V.</given-names></name>
<name><surname>Dronkers</surname><given-names>N.F.</given-names></name>
<name><surname>Gabrieli</surname><given-names>J.D.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Cognitive processing speed and the structure of white matter pathways: convergent evidence from normal variation and lesion studies</article-title>. <source>Neuroimage</source> <volume>42</volume>: <fpage>1032</fpage>–<lpage>1044</lpage>.</citation>
</ref>
<ref id="bibr66-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wake</surname><given-names>H.</given-names></name>
<name><surname>Lee</surname><given-names>P.R.</given-names></name>
<name><surname>Fields</surname><given-names>R.D.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Control of local protein synthesis and initial events in myelination by action potentials</article-title>. <source>Science</source> <volume>333</volume>: <fpage>1647</fpage>–<lpage>1651</lpage>.</citation>
</ref>
<ref id="bibr67-1756285612454323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yücel</surname><given-names>M.</given-names></name>
<name><surname>Takagi</surname><given-names>M.</given-names></name>
<name><surname>Walterfang</surname><given-names>M.</given-names></name>
<name><surname>Lubman</surname><given-names>D.I.</given-names></name>
</person-group> (<year>2008</year>). <article-title>Toluene misuse and long-term harms: a systematic review of the neuropsychological and neuroimaging literature</article-title>. <source>Neurosci Biobehav Rev</source> <volume>32</volume>: <fpage>910</fpage>–<lpage>926</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>